MDS Nordion to Host Physician Expert Teams from Banner Good Samaritan Medical Center and UNC School of Medicine at SIR 2009
MDS Nordion event information for the Society of Interventional Radiology 2009 Scientific Meeting.
Ottawa, Canada, March 07, 2009 --(PR.com)-- MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, will play host to a team of physician experts from Banner Good Samaritan Medical Center in Phoenix, AZ, and the UNC School of Medicine, University of North Carolina – Chapel Hill, at its booth and in the Press Room during the upcoming Society of Interventional Radiology 2009 (SIR 2009) Scientific Meeting in San Diego, CA.
Media, analysts, and attendees are invited to meet and engage with MDS Nordion company executives and Banner Good Samaritan Medical Center and UNC School of Medicine physician experts on the SIR 2009 expo floor.
Who: MDS Nordion company executives and leading physicians including Dr. David Wood, Chief of Interventional Radiology, Banner Good Samaritan Medical Center; Dr. Kevin Hirsch, Chairman, Department of Radiology, Banner Good Samaritan Medical Center; and Dr. Matthew A. Mauro, Professor and Chair, Department of Radiology, UNC School of Medicine, University of North Carolina, Chapel Hill.
What: The first hospital in the Western U.S. to offer TheraSphere®, MDS Nordion’s flagship primary liver cancer therapy. Banner Good Samaritan physicians will share real-world insight and experiences with the use of TheraSphere in their clinical practices. The world-renowned UNC School of Medicine will share additional clinical expertise.
Where: Booth 2430, San Diego Convention Center, San Diego, CA
SIR 2009 Press Room, Room 15B, San Diego Convention Center, San Diego, CA
When: Sunday, March 8, 12:00 – 1:30 PM PST (expo floor)
Monday, March 9, 12:00 – 1:00 PM PST (expo floor)
Monday, March 9, 12:00 PM PST (press room)
Event: Society of Interventional Radiology 2009 Scientific Meeting
Contact: For more information or advance meeting scheduling with MDS Nordion and Banner Good Samaritan and UNC School of Medicine physicians, please contact Melissa A. Drozdowski, Interprose Public Relations at 336-376-5318 or mdrozdowski@interprosepr.com.
For additional information during SIR 2009 or on-site scheduling, please contact Shelley Maclean, MDS Nordion at 613-291-3689 or shelley.maclean@mdsinc.com.
About TheraSphere®
TheraSphere® is a low toxicity, liver cancer therapy which consists of millions of micro-glass beads containing radioactive yttrium-90. The product is injected by physicians into the main artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood vessels. Unlike chemotherapy, it has few side effects. Patients rarely experience nausea and vomiting usually associated with high-dose, systemic chemotherapies. The TheraSphere® treatment can generally be administered on an outpatient basis and does not usually require an overnight hospital stay. TheraSphere®, 100% reimbursed by Medicare and many commercial health insurers, is approved in the U.S. as a Humanitarian Device for the treatment of hepatocellular carcinoma, also referred to as primary liver cancer, and is now approved for patients who also have partial or branch portal vein thrombosis and who are identified as suitable candidates by their physicians.
Media Contacts:
Melissa A. Drozdowski, Interprose PR for MDS Nordion
P: 336-376-5318
C: 336-266-2549
E: mdrozdowski@interprosepr.com
Shelley Maclean, MDS Nordion
C: 613-291-3689
E: Shelley.maclean@mdsinc.com
###
Media, analysts, and attendees are invited to meet and engage with MDS Nordion company executives and Banner Good Samaritan Medical Center and UNC School of Medicine physician experts on the SIR 2009 expo floor.
Who: MDS Nordion company executives and leading physicians including Dr. David Wood, Chief of Interventional Radiology, Banner Good Samaritan Medical Center; Dr. Kevin Hirsch, Chairman, Department of Radiology, Banner Good Samaritan Medical Center; and Dr. Matthew A. Mauro, Professor and Chair, Department of Radiology, UNC School of Medicine, University of North Carolina, Chapel Hill.
What: The first hospital in the Western U.S. to offer TheraSphere®, MDS Nordion’s flagship primary liver cancer therapy. Banner Good Samaritan physicians will share real-world insight and experiences with the use of TheraSphere in their clinical practices. The world-renowned UNC School of Medicine will share additional clinical expertise.
Where: Booth 2430, San Diego Convention Center, San Diego, CA
SIR 2009 Press Room, Room 15B, San Diego Convention Center, San Diego, CA
When: Sunday, March 8, 12:00 – 1:30 PM PST (expo floor)
Monday, March 9, 12:00 – 1:00 PM PST (expo floor)
Monday, March 9, 12:00 PM PST (press room)
Event: Society of Interventional Radiology 2009 Scientific Meeting
Contact: For more information or advance meeting scheduling with MDS Nordion and Banner Good Samaritan and UNC School of Medicine physicians, please contact Melissa A. Drozdowski, Interprose Public Relations at 336-376-5318 or mdrozdowski@interprosepr.com.
For additional information during SIR 2009 or on-site scheduling, please contact Shelley Maclean, MDS Nordion at 613-291-3689 or shelley.maclean@mdsinc.com.
About TheraSphere®
TheraSphere® is a low toxicity, liver cancer therapy which consists of millions of micro-glass beads containing radioactive yttrium-90. The product is injected by physicians into the main artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood vessels. Unlike chemotherapy, it has few side effects. Patients rarely experience nausea and vomiting usually associated with high-dose, systemic chemotherapies. The TheraSphere® treatment can generally be administered on an outpatient basis and does not usually require an overnight hospital stay. TheraSphere®, 100% reimbursed by Medicare and many commercial health insurers, is approved in the U.S. as a Humanitarian Device for the treatment of hepatocellular carcinoma, also referred to as primary liver cancer, and is now approved for patients who also have partial or branch portal vein thrombosis and who are identified as suitable candidates by their physicians.
Media Contacts:
Melissa A. Drozdowski, Interprose PR for MDS Nordion
P: 336-376-5318
C: 336-266-2549
E: mdrozdowski@interprosepr.com
Shelley Maclean, MDS Nordion
C: 613-291-3689
E: Shelley.maclean@mdsinc.com
###
Contact
MDS Nordion
Melissa A. Drozdowski
336-376-5318
www.mds.nordion.com/
Melissa A. Drozdowski
336-376-5318
www.mds.nordion.com/
Contact
Categories